Discover the latest news from iBio Inc, a biotechnology company, here:
iBio Inc’s Machine Learning Model Granted Patent By USPTO
iBio has been issued a US patent for its machine learning model to design engineered epitopes, allowing precise therapeutic antibody steering towards specific regions of a target protein. The patent solidifies iBio’s position as a leader in AI-driven drug discovery and provides the company with a competitive advantage as it continues to build its pipeline of immunotherapies. iBio’s RubrYc Discovery Engine uses proprietary epitope steering technology, a specialized antibody library, and AI-powered optimization to quickly identify and optimize molecules that can effectively address challenging drug targets.